The identification and evaluation of botanical drugs for treatment of FGFR3 activating mutation related skeletal dysplasias and cancers
Docket Number:12T-1020306
Inventor:Yuan-Tsong Chen, Yi-Ching Lee
IP Status:Know-how
Abstract:
We have established a high throughput cell-based assay system for quantitative evaluation the FGFR3 activity and screening for molecules affected FGFR3 activation. We also established a human achondroplasia mouse model for the assessment of the potential therapeutic approaches for treatment of human skeletal dysplasias. Using these systems we identified active fractions from plants to inhibit the FGFR3 activation. The active fractions have been validated in human FGFR3 activation multiple myeloma cancer cells and the human achondroplasia mouse model and can be further developed into botanical drugs for the treatment of FGFR3 related skeletal dysplasias and associated human cancers.
Fields of Application:
Drug screening, disease animal model, pre-clinical animal evaluation, diseases and cancer treatment for FGFR3 activation related skeletal dysplasias and cancers.
Advantages when compared to the existing technologies:
- No cell-based screening system for evaluating the FGFR3 activities.
- No mouse model designed to evaluate the therapies targeting to human FGFR3 activation.
- The only botanical drugs for treatment of human skeletal dysplasias.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
